We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
In this research letter, the authors highlight their retrospective study examining their hypothesis that high-flow nasal cannula (HFNC) reduces intubation rates and mortality in patients with COVID-19–related respiratory failure. They found that intubation rates were decreased in patients who received HFNC (55% vs 72%), but mortality rates were similar.
Although a retrospective design, this study supports evidence for the use of HFNC to reduce intubation rates in patients with COVID-19 respiratory failure; similar to other studies looking at HFNC in hypoxemic respiratory failure, this study does not show a reduction in mortality.
– Morgan Soffler, MD
This abstract is available on the publisher's site.
Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. In severe de novo acute hypoxemic respiratory failure, high flow nasal cannula oxygen (HFNC) improves oxygenation, reduces minute ventilation, and work of breathing (1, 2). In addition, the technique has demonstrated clinical benefits in such patients (3, 4).
To test the hypothesis that HFNC reduces intubation rate and mortality in patients with COVID-19 admitted to the intensive care unit (ICU) for acute respiratory failure, we designed this retrospective study that compares patients who received HFNC to those who did not in a cohort of 379 critically ill patients.
American Journal of Respiratory and Critical Care Medicine
High Flow Nasal Canula in Critically Ill Severe COVID-19 Patients
Am J Respir Crit Care Med 2020 Aug 06;[EPub Ahead of Print], A Demoule, A Vieillard Baron, M Darmon, A Beurton, G Géri, G Voiriot, T Dupont, L Zafrani, L Girodias, V Labbé, M Dres, M Fartoukh, E Azoulay